Pacira BioSciences (PCRX) Q2 FY26 earnings call

Pacira BioSciences delivered solid Q2 FY26 results, demonstrating disciplined execution of its 5x30 strategy. The company advanced its pipeline with key clinical readouts expected later this year and strengthened its financial position through the strategic divestiture of Iovera. Despite macroeconomic headwinds impacting certain elective procedures, commercial momentum was sustained, particularly in outpatient settings and through expanded payer access.